CDK7 inhibitor

DRUG CLASS:

CDK7 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Triple Negative Breast Cancer	No biomarker	Triple Negative Breast Cancer	CT7001 Sensitive: B - Late Trials CT7001 Sensitive : B	CT7001 Sensitive: B - Late Trials CT7001 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CT7001 Sensitive: B - Late Trials CT7001 Sensitive : B	CT7001 Sensitive: B - Late Trials CT7001 Sensitive : B
IDH2 mutation	Glioma	IDH2 mutation	Glioma	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2	TG02 Sensitive: C2 – Inclusion Criteria TG02 Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	SY-5609 Sensitive: C2 – Inclusion Criteria SY-5609 Sensitive : C2	SY-5609 Sensitive: C2 – Inclusion Criteria SY-5609 Sensitive : C2
IDH1 mutation	Glioma	IDH1 mutation	Glioma	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3	TG02 Sensitive: C3 – Early Trials TG02 Sensitive : C3
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	CT7001 Sensitive: C3 – Early Trials CT7001 Sensitive : C3	CT7001 Sensitive: C3 – Early Trials CT7001 Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3	BTX-A51 Sensitive: C3 – Early Trials BTX-A51 Sensitive : C3
CDK7 overexpression	Cholangiocarcinoma	CDK7 overexpression	Cholangiocarcinoma	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D
MYC amplification	Triple Negative Breast Cancer	MYC amplification	Triple Negative Breast Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Hepatocellular Cancer	MYC amplification	Hepatocellular Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Estrogen Receptor Positive Breast Cancer	MYC amplification	Estrogen Receptor Positive Breast Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Pancreatic Cancer	MYC amplification	Pancreatic Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Prostate Cancer	MYC amplification	Prostate Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
MYC amplification	Ovarian Cancer	MYC amplification	Ovarian Cancer	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D	YPN-005 Sensitive: D – Preclinical YPN-005 Sensitive : D
BRAF mutation	Colorectal Cancer	BRAF mutation	Colorectal Cancer	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D	SY-5609 Sensitive: D – Preclinical SY-5609 Sensitive : D
AR expression	Prostate Cancer	AR expression	Prostate Cancer	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D	SY‑079 Sensitive: D – Preclinical SY‑079 Sensitive : D
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	Q901 Sensitive: D – Preclinical Q901 Sensitive : D	Q901 Sensitive: D – Preclinical Q901 Sensitive : D
CD133 positive	Glioblastoma	CD133 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
CD44 positive	Glioblastoma	CD44 positive	Glioblastoma	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D	CYC065 + SY‑079 Sensitive: D – Preclinical CYC065 + SY‑079 Sensitive : D
AR positive	Triple Negative Breast Cancer	AR positive	Triple Negative Breast Cancer	enzalutamide + KRLS-017 Sensitive: D – Preclinical enzalutamide + KRLS-017 Sensitive : D	enzalutamide + KRLS-017 Sensitive: D – Preclinical enzalutamide + KRLS-017 Sensitive : D

CDK7 inhibitor

CDK7 inhibitor

Associations(22)

Associations
(22)